From Uni Spinout To Acquisition

Kynos Therapeutics is a clinical-stage biotech developing first-in-class medicines at the interface of inflammation, immunity, and metabolism. Spun out of the University of Edinburgh in 2022 with backing from Epidarex Capital, IP Group, and Scottish Enterprise.

DIAGNOSIS

A 15-year KMO inhibitor programme with GSK collaboration. But academic credibility doesn't translate to commercial positioning. With only a logo in place, Kynos needed to communicate complex therapeutic science to investors, pharma partners, and the clinical community. Nothing in the brand was doing that.

The problem wasn't the science. It was the story and how they delivered it.

THE SYSTEM

We built a brand that translated science into commercial positioning.

Visual identity and website designed to convey clinical-stage credibility while differentiating Kynos in a competitive biotech landscape.

A digital platform to support investor communications, partnership discussions, and clinical development milestones — built for the conversations that secure funding and close acquisitions.